PharmaCieloPCLOF +24.74% EV-to-EBITDA is 179.57 as of Jul. 08, 2026. The stock has 5 warning signs investors should review. Among 740 Drug Manufacturers companies, PharmaCielo ranks worse than 97.16% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PharmaCielo's enterprise value is $25.32 Mil.
PharmaCielo's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $0.14 Mil. Therefore, PharmaCielo's EV-to-EBITDA for today is 179.57.
The historical rank and industry rank for PharmaCielo's EV-to-EBITDA or its related term are showing as below:
PCLOF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -165.14 Med: -4.79 Max: 179.57
Current: 179.57
During the past 7 years, the highest EV-to-EBITDA of PharmaCielo was 179.57. The lowest was -165.14. And the median was -4.79.
PCLOF's EV-to-EBITDA is ranked worse than 97.16% of 740
companies
in the Drug Manufacturers industry
Industry Median: 12.955
vs PCLOF: 179.57
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PharmaCielo's PE Ratio (TTM) for today is calculated as:
PharmaCielo's share price for today is $0.06555.
PharmaCielo's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.009.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for PharmaCielo's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PharmaCielo's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCielo EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PharmaCielo's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PharmaCielo's EV-to-EBITDA falls into.
PharmaCielo's current Enterprise Value is $25.32 Mil.
PharmaCielo's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCielo (PCLOF) has a EV-to-EBITDA of 179.57 as of Jul. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PharmaCielo. According to the industry distribution chart, PharmaCielo ranks #719 out of 740 companies in the Drug Manufacturers industry, placing it in the top 97.2%.
Is PharmaCielo's EV-to-EBITDA too high?
PharmaCielo's current EV-to-EBITDA is 179.57. The Drug Manufacturers industry median EV-to-EBITDA is 12.96. PharmaCielo's value of 179.57 is 1286.1% above this industry median. Based on the distribution chart, PharmaCielo ranks #719 out of 740 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does PharmaCielo's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PharmaCielo ranks #719 out of 740 companies for EV-to-EBITDA. This places PharmaCielo in the lower half of its industry. The industry median EV-to-EBITDA is 12.96. PharmaCielo's value of 179.57 is 1286.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.96, based on 740 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaCielo's current EV-to-EBITDA of 179.57 is 1286.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PharmaCielo. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCielo's current EV-to-EBITDA is 179.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCielo stock overvalued right now?
Based on GuruFocus' analysis, PharmaCielo (PCLOF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.09, compared to a current price of $0.07 — trading 27.2% below its estimated fair value. The current EV-to-EBITDA is 179.57 and 1286.1% above the Drug Manufacturers industry median of 12.96. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For PharmaCielo (PCLOF), the current EV-to-EBITDA is 179.57 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico and generates the majority of its revenue in the form of the Sale of Cannabis derivative products in America followed by Australia, Africa and Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCLOF has been successfully added to your 